Proprietary Product Development

Arecor is committed to leveraging its ArestatTM platform to develop a portfolio of proprietary products enabling improved treatment for diabetes care via the innovative reformulations of approved proteins and peptides.

Technology Partnering

Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would simply not be possible using conventional formulation science.



What is Diabetes?

Diabetes is a chronic condition that affects the body’s ability to control blood sugar level. If left untreated it can lead to serious health complications.

  • Ultra-Rapid Acting Insulin

    Significantly faster onset of action

    Improved glycemic control

    Desired advancement for artificial pancreas

  • Ultra-Concentrated Rapid Acting Insulin

    Critical for miniaturisation of delivery devices

    Superior fast acting insulin for high dose users


  • High concentration antibodies

    Most biotherapeutic products in development are monoclonal antibodies or related…

  • Lyophilised powder to liquid switch

    There is a clear need within the pharmaceutical industry to…

  • Intravenous to subcutaneous switch

    There are a broad range of biotherapeutic products both on…

  • Differentiated biosimilars with IP Protection

    The biosimilars market is a complex, highly competitive yet significant…

  • Superior peptides

    INSULINS & OTHER DIABETES PEPTIDES Arecor is leveraging its unique…

  • Thermostable therapeutics

    Most biotherapeutic products, particularly in liquid form, require refrigeration for…

Latest News and Events

  • 19th March 2020

    Arecor extends multi-product collaboration with clinical stage biotech

  • 25th February 2020

    Arecor achieves second license milestone payment from global pharmaceutical partner

  • 13th February 2020

    Arecor signs a new feasibility study agreement with top five pharma company